| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5753675 | KOWA CO | Quinoline analogs of mevalonolactone and derivatives thereof |
May, 2015
(8 years ago) | |
| US5856336 | KOWA CO | Quinoline type mevalonolactones |
Dec, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5854259 | KOWA CO | Quinoline type mevalonolactones |
Dec, 2015
(8 years ago) | |
| US6465477 | KOWA CO | Stable pharmaceutical composition |
Dec, 2016
(7 years ago) | |
|
US5856336 (Pediatric) | KOWA CO | Quinoline type mevalonolactones |
Jun, 2021
(2 years ago) | |
| US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(2 months ago) | |
| US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(a month ago) | |
|
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(3 months from now) | |
|
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(3 months from now) | |
Livalo is owned by Kowa Co.
Livalo contains Pitavastatin Calcium.
Livalo has a total of 9 drug patents out of which 7 drug patents have expired.
Expired drug patents of Livalo are:
- US5854259
- US6465477
- US5856336*PED
- US8557993
- US7022713
- US5753675
- US5856336
Livalo was authorised for market use on 03 August, 2009.
Livalo is available in tablet;oral dosage forms.
Livalo can be used as adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia.
Drug patent challenges can be filed against Livalo from 16 November, 2021.
The generics of Livalo are possible to be released after 19 August, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 16, 2022 |
| Pediatric Exclusivity(PED) | Nov 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2014 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
NCE-1 date: 16 November, 2021
Market Authorisation Date: 03 August, 2009
Treatment: Adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemi...
Dosage: TABLET;ORAL
LIVALO family patents
